Annexon Inc (ANNX)

$4.96 +0.07 (1.43%)
Market Cap 585.01M
Revenue (ttm) 0.00
Net Income (ttm) -138.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,674,600
Avg Vol 2,559,470
Day's Range N/A - N/A
Shares Out 119.63M
Stochastic %K 19%
Beta 1.17
Analysts Strong Sell
Price Target $14.71

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also devel...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5500
Fax: 650 636 9773
Address:
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States
Thomas105
Thomas105 Feb. 24 at 8:30 PM
$ANNX Will the price remain at around 5? If so, there's potential for upward movement. Hoping for new price targets after Q4 and Cowen HCConference as short-term catalysts.
0 · Reply
Thomas105
Thomas105 Feb. 24 at 1:16 PM
$ANNX https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-present-td-cowen-46th-annual-health-care
0 · Reply
Astrobro
Astrobro Feb. 23 at 4:57 AM
$ANNX Will 100% go long on this in the summer. too early for now
0 · Reply
Lightening_strikes
Lightening_strikes Feb. 20 at 2:58 PM
$ANNX what junk
0 · Reply
Thomas105
Thomas105 Feb. 20 at 12:38 PM
$ANNX Premarket activity unusual Some news today?
1 · Reply
Thomas105
Thomas105 Feb. 18 at 12:11 AM
$ANNX https://ir.annexonbio.com/news-releases/news-release-details/annexon-host-person-and-virtual-kol-event-discuss-vonaprument
0 · Reply
Lightening_strikes
Lightening_strikes Feb. 13 at 5:26 PM
$ANNX pathetic
0 · Reply
Thomas105
Thomas105 Feb. 13 at 10:58 AM
$ANNX Someone's trying to pull us below 5. maybe to early to load up. big bid
2 · Reply
BooEmmy
BooEmmy Feb. 12 at 7:55 PM
$ANNX Thinking this is a good place to load up before the major move up to $20. imho
1 · Reply
Lightening_strikes
Lightening_strikes Feb. 11 at 6:05 PM
$ANNX why is this down 9%
0 · Reply
Latest News on ANNX
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 22 hours ago

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Feb 17, 2026, 8:00 AM EST - 7 days ago

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Jan 24, 2026, 2:08 AM EST - 4 weeks ago

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 5:05 PM EST - 5 weeks ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 5:06 PM EST - 5 weeks ago

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Jan 8, 2026, 8:00 AM EST - 6 weeks ago

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:05 PM EST - 6 weeks ago

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 7:31 PM EST - 2 months ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Nov 20, 2025, 5:23 PM EST - 3 months ago

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Nov 14, 2025, 4:01 PM EST - 3 months ago

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 10:55 PM EST - 3 months ago

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 4:12 PM EST - 3 months ago

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Nov 10, 2025, 4:05 PM EST - 3 months ago

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:58 PM EDT - 6 months ago

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:38 AM EDT - 6 months ago

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 6 months ago

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Aug 14, 2025, 4:05 PM EDT - 6 months ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Aug 7, 2025, 4:30 PM EDT - 7 months ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 24, 2025, 7:00 AM EDT - 7 months ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Jul 14, 2025, 12:47 PM EDT - 8 months ago

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Jun 18, 2025, 4:05 PM EDT - 8 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 9 months ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025, 4:05 PM EDT - 10 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025, 8:00 AM EDT - 10 months ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 9, 2025, 5:00 PM EDT - 10 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 7, 2025, 8:00 AM EDT - 10 months ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Apr 15, 2025, 7:12 AM EDT - 11 months ago

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 11 months ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 11 months ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Mar 3, 2025, 8:00 AM EST - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Feb 13, 2025, 8:30 AM EST - 1 year ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Dec 16, 2024, 7:30 AM EST - 1 year ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 14, 2024, 8:00 AM EST - 1 year ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 21, 2024, 8:00 PM EDT - 1 year ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Oct 3, 2024, 1:20 AM EDT - 1 year ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17, 2024, 9:28 AM EDT - 1 year ago

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jul 11, 2024, 6:09 PM EDT - 1 year ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 25, 2024, 5:00 PM EDT - 1 year ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 5, 2024, 11:04 PM EDT - 1 year ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 5:06 PM EDT - 1 year ago

Annexon Announces Proposed Public Offering of Common Stock

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 4, 2024, 2:07 PM EDT - 1 year ago

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 4, 2024, 7:11 AM EDT - 1 year ago

Annexon's neurological disorder drug meets main goal of late-stage study

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 13, 2024, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 7, 2024, 12:30 PM EDT - 1 year ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Thomas105
Thomas105 Feb. 24 at 8:30 PM
$ANNX Will the price remain at around 5? If so, there's potential for upward movement. Hoping for new price targets after Q4 and Cowen HCConference as short-term catalysts.
0 · Reply
Thomas105
Thomas105 Feb. 24 at 1:16 PM
$ANNX https://ir.annexonbio.com/news-releases/news-release-details/annexon-biosciences-present-td-cowen-46th-annual-health-care
0 · Reply
Astrobro
Astrobro Feb. 23 at 4:57 AM
$ANNX Will 100% go long on this in the summer. too early for now
0 · Reply
Lightening_strikes
Lightening_strikes Feb. 20 at 2:58 PM
$ANNX what junk
0 · Reply
Thomas105
Thomas105 Feb. 20 at 12:38 PM
$ANNX Premarket activity unusual Some news today?
1 · Reply
Thomas105
Thomas105 Feb. 18 at 12:11 AM
$ANNX https://ir.annexonbio.com/news-releases/news-release-details/annexon-host-person-and-virtual-kol-event-discuss-vonaprument
0 · Reply
Lightening_strikes
Lightening_strikes Feb. 13 at 5:26 PM
$ANNX pathetic
0 · Reply
Thomas105
Thomas105 Feb. 13 at 10:58 AM
$ANNX Someone's trying to pull us below 5. maybe to early to load up. big bid
2 · Reply
BooEmmy
BooEmmy Feb. 12 at 7:55 PM
$ANNX Thinking this is a good place to load up before the major move up to $20. imho
1 · Reply
Lightening_strikes
Lightening_strikes Feb. 11 at 6:05 PM
$ANNX why is this down 9%
0 · Reply
Lightening_strikes
Lightening_strikes Feb. 10 at 8:54 PM
$ANNX any catalysts 1h2026?
1 · Reply
Determinedstocks
Determinedstocks Feb. 5 at 8:36 PM
$ANNX Had to step in and pick up a few shares. Thinking this is going down more before it goes back up.
0 · Reply
WinStreakWiz
WinStreakWiz Feb. 4 at 3:13 PM
$ANNX is a clinical-stage biotech developing therapies for epilepsy and depression; its pipeline is in mid-stage trials, representing a binary investment based on clinical outcomes.
1 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 10:13 AM
$ANNX Outstanding article that hits the mark on ANNX's current state. So if you want to refresh your ANNX insights or learn about ANNX from scratch, this is a must read. https://everyticker.com/quote/ANNX/analysis/annexon-unlocking-the-classical-complement-pathway-with-key-catalysts-on-the-horizon-annx
0 · Reply
Sowa5000
Sowa5000 Feb. 3 at 11:16 PM
$ANNX Got a solid pipeline. Undervalued adding long calls!
1 · Reply
Lightening_strikes
Lightening_strikes Feb. 1 at 11:44 AM
$ANNX any near term catalysts or all back half 2026.
1 · Reply
Lightening_strikes
Lightening_strikes Jan. 30 at 9:07 PM
$ANNX crushed today
0 · Reply
Consti22
Consti22 Jan. 29 at 9:24 PM
$ANNX
0 · Reply
Lightening_strikes
Lightening_strikes Jan. 28 at 8:51 PM
$ANNX need news for next leg up
0 · Reply
Montu11
Montu11 Jan. 27 at 4:31 PM
$ANNX wake me up when we’re at $15 🫩🥱😴
0 · Reply
Thomas105
Thomas105 Jan. 26 at 8:44 PM
$ANNX nice hammer on the way tomorrow hit 7 again
0 · Reply
makingdoughfromoptions
makingdoughfromoptions Jan. 26 at 8:14 PM
$ANNX $12 calls for Dec paying $2.00 or bit more. Net cost, $4.50-60. IF called, a near triple. If not called, your options expire and your new cost is $4.50. I sold 57 contracts. But my net cost is now $2.75 or so.
0 · Reply